ModernGraham Valuation

Company Name:

IDEXX Laboratories, Inc.



Company Ticker IDXX

3/6/2017 Date of Analysis

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

Adequate Size of the Enterprise	Market Cap > \$2Bil	\$13,035,063,265 Pas	S
2. Sufficiently Strong Financial Condition	Current Ratio > 2	0.90 Fail	
3. Earnings Stability	Positive EPS for 10 years prior	Pas	ss
4. Dividend Record	Dividend Payments for 10 years prior	Fail	
	Increase of 33% in EPS in past 10		
	Increase of 33% in EPS in past 10 years using 3 year averages at		

5. Earnings Growth 136.48% Pass beginning and end 61.75 Fail 6. Moderate PEmg Ratio PEmg < 20 7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 -123.37 Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1.	Sufficiently Strong Financial Condition	Current Ratio > 1.5	0.90	Fail
2.	Sufficiently Strong Financial Condition	Debt to NCA < 1.1	-6.67	Fail
3.	Earnings Stability	Positive EPS for 5 years prior		Pass
4.	Dividend Record	Currently Pays Dividend		Fail
5.	Earnings Growth	EPSmg greater than 5 years ago		Pass

Score

Suitability

Defensive No Enterprising No

Stage 2: Determination of Intrinsic Value

EPSmg	\$2.38
MG Growth Estimate	8.73%
MG Value	\$61.84
MG Value based on 3% Growth	\$34.54
MG Value based on 0% Growth	\$20.25
Market Implied Growth Rate	26.62%

MG Opinion

Current Price \$147.08 % of Intrinsic Value 237.85% Opinion Overvalued

MG Grade

Stage 3: Information for Further Research


Net Current Asset Value (NCAV)	-\$8.73
Graham Number	\$0.00
PEmg	61.75
Current Ratio	0.90
PB Ratio	-123.37
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0

Morningstar

Useful Links: ModernGraham tagged articles

> Google Finance **MSN Money** Yahoo Finance Seeking Alpha **GuruFocus SEC Filings**

EPS History		EPSmg History	
Next Fiscal Year			
Estimate	• • • •	Next Fiscal Year Estimate	\$2.38
Dec2016	\$2.44	Dec2016	\$2.06
Dec2015	\$2.05	Dec2015	\$1.81
Dec2014	\$1.79	Dec2014	\$1.64
Dec2013	\$1.74	Dec2013	\$1.51
Dec2012	\$1.59	Dec2012	\$1.33
Dec2011	\$1.39	Dec2011	\$1.15
Dec2010	\$1.19	Dec2010	\$0.99
Dec2009	\$1.01	Dec2009	\$0.86
Dec2008	\$0.94	Dec2008	\$0.76
Dec2007	\$0.73	Dec2007	\$0.65
Dec2006	\$0.71	Dec2006	\$0.57
Dec2005	\$0.58	Dec2005	\$0.48
Dec2004	\$0.55	Dec2004	\$0.41
Dec2003	\$0.40	Dec2003	\$0.32
Dec2002	\$0.33	Dec2002	\$0.25
Dec2001	\$0.27	Dec2001	\$0.18
Dec2000	\$0.26	Balance Sheet Information	12/1/2016
Dec1999	\$0.21	Total Current Assets	\$845,584,000
Dec1998	-\$0.10	Total Current Liabilities	\$934,568,000
Dec1997	-\$0.14	Long-Term Debt	\$593,110,000
		Total Assets	\$1,530,704,000
		Intangible Assets	\$224,383,000
		Total Liabilities	\$1,639,056,000
		Shares Outstanding (Diluted Average)	90,884,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company #N/A

Other ModernGraham posts about related companies

 $\underline{\textit{Mettler-Toledo International Inc Valuation} - \textit{Initial Coverage \$MTD}}$

<u>Envision Healthcare Corp Valuation – Initial Coverage \$EVHC</u>

<u>UnitedHealth Group Inc Valuation – February 2017 \$UNH</u>

Davita Inc Valuation - February 2017 \$DVA

Steris PLC Valuation - Initial Coverage \$STE

<u>Danaher Corporation Valuation – February 2017 \$DHR</u>

<u>Cryolife Inc Valuation – Initial Coverage \$CRY</u>

CorVel Corp Valuation - Initial Coverage \$CRVL

<u>Charles River Laboratories Intl Inc Valuation – Initial Coverage \$CRL</u>

<u>Kindred Healthcare Inc Valuation – Initial Coverage \$KND</u>